IMC Logo.jpg
Immuron Plans Phase 3 trial for IMM-124E to Prevent Travelers’ Diarrhea
November 21, 2019 07:00 ET | Immuron Limited
Key Points Immuron completes first meeting with FDA on development of IMM-124E as product to specifically prevent Travelers’ Diarrhea (TD)Phase 3 clinical trial of IMM-124E to prevent TD planned for...
IMC Logo.jpg
U.S. Defense Reports Immuron’s Travelan® demonstrates broad reactivity to Vibrio cholera strains from Southeast Asia indicating broad potential for prevention of travelers’ diarrhea
September 04, 2019 06:00 ET | Immuron Limited
Key Highlights: Major goal of study was to evaluate Travelan®’s ability to bind and react to a variety of infectious Vibrio cholera strains from Southeast Asia Pathogenic bacteria evaluated in study...